---
title: "Earnings Summary: Jazz Pharmaceuticals Q4"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/276786346.md"
description: "Jazz Pharmaceuticals (NASDAQ:JAZZ) reported Q4 earnings on February 24, 2026, beating estimates by 7.79% with an EPS of $6.64 compared to the expected $6.16. Revenue increased by $109 million year-over-year. In the previous quarter, the company also exceeded EPS estimates by $2.7, but shares dropped 2.31% the following day. Past performance shows fluctuations in EPS and revenue across recent quarters. For more earnings updates, visit Jazz Pharmaceuticals' earnings calendar."
datetime: "2026-02-24T21:08:13.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/276786346.md)
  - [en](https://longbridge.com/en/news/276786346.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/276786346.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/276786346.md) | [繁體中文](https://longbridge.com/zh-HK/news/276786346.md)


# Earnings Summary: Jazz Pharmaceuticals Q4

The Q4 earnings report for **Jazz Pharmaceuticals** (NASDAQ:JAZZ) was released on Tuesday, February 24, 2026 at 04:05 PM.

Here's what investors need to know about the latest announcement.

### Earnings

Jazz Pharmaceuticals beat estimated earnings by 7.79%, reporting an EPS of $6.64 versus an estimate of $6.16.

Revenue was up $109.00 million from the same period last year.

### Overview of Past Earnings

The company beat on EPS by $2.7 in the previous quarter, leading to a 2.31% drop share price change the next day.

Here's a look at Jazz Pharmaceuticals's past performance:

**Quarter**

**Q3 2025**

**Q2 2025**

**Q1 2025**

**Q4 2024**

**EPS Estimate**

5.43

\-6.34

4.66

5.81

**EPS Actual**

8.13

\-8.25

1.68

6.60

**Revenue Estimate**

1.11B

1.05B

983.75M

1.06B

**Revenue Actual**

1.13B

1.05B

897.84M

1.09B

To track all earnings releases for Jazz Pharmaceuticals visit their earnings calendar here.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

### Related Stocks

- [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/en/quote/PBE.US.md)
- [Vanguard Health Care ETF (VHT.US)](https://longbridge.com/en/quote/VHT.US.md)
- [iShares Global Healthcare ETF (IXJ.US)](https://longbridge.com/en/quote/IXJ.US.md)
- [VanEck Biotech ETF (BBH.US)](https://longbridge.com/en/quote/BBH.US.md)
- [State Street®HlthCrSelSectSPDR®ETF (XLV.US)](https://longbridge.com/en/quote/XLV.US.md)
- [First Trust NYSE Arca Biotech ETF (FBT.US)](https://longbridge.com/en/quote/FBT.US.md)
- [iShares US Pharmaceuticals ETF (IHE.US)](https://longbridge.com/en/quote/IHE.US.md)
- [Invesco Nasdaq Biotechnology ETF (IBBQ.US)](https://longbridge.com/en/quote/IBBQ.US.md)
- [ALPS Medical Breakthroughs ETF (SBIO.US)](https://longbridge.com/en/quote/SBIO.US.md)
- [State Street® SPDR® S&P® Biotech ETF (XBI.US)](https://longbridge.com/en/quote/XBI.US.md)
- [ProShares Ultra Nasdaq Biotechnology (BIB.US)](https://longbridge.com/en/quote/BIB.US.md)
- [Jazz Pharmaceuticals plc (JAZZ.US)](https://longbridge.com/en/quote/JAZZ.US.md)
- [ARK Genomic Revolution ETF (ARKG.US)](https://longbridge.com/en/quote/ARKG.US.md)
- [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/en/quote/IBB.US.md)

## Related News & Research

- [Senti Biosciences Non-GAAP EPS of -$0.53 misses by $0.06](https://longbridge.com/en/news/280788653.md)
- [Tritonpoint Wealth LLC Sells 10,771 Shares of Zoetis Inc. $ZTS](https://longbridge.com/en/news/281684930.md)
- [PepGen Reports Encouraging Phase II FREEDOM2 DM1 Data at 5 mg/kg; 10 mg/kg Cohort Underway](https://longbridge.com/en/news/281268875.md)
- [BUZZ-Context Therapeutics rises as FDA grants fast-track status to ovarian cancer drug](https://longbridge.com/en/news/281517197.md)
- [Iterum Therapeutics Received Notice of Delisting](https://longbridge.com/en/news/281174211.md)